Related Experiment Video
Updated: Sep 29, 2025

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
Published on: November 17, 2018
LDL as a therapeutic target
Ángel Díaz Rodríguez1, Teresa Mantilla Morató2
1Médico de Familia, Centro Salud de Bembibre, profesor Universidad de León, Ponferrada, León, España.
Insights
Atherosclerotic cardiovascular disease (ASCVD) is rising, with dyslipidemia as a key risk factor. New treatments like PCSK9 inhibitors offer advanced LDL lowering, complementing statins for ASCVD prevention.
Area of Science:
- Cardiology
- Metabolic Disorders
- Public Health
Background:
- Atherosclerotic cardiovascular disease (ASCVD) incidence is increasing globally, particularly in developed nations.
- Dyslipidemia, characterized by abnormal blood lipid levels, is a primary risk factor for ASCVD.
- Lowering low-density lipoprotein (LDL) cholesterol is a critical objective in managing dyslipidemia and preventing ASCVD.
Purpose of the Study:
- To review the current landscape of dyslipidemia management for ASCVD risk reduction.
- To highlight the role of statins and emerging therapies like PCSK9 inhibitors.
- To emphasize the importance of personalized treatment goals based on clinical guidelines.
Main Methods:
- Review of current medical literature and clinical guidelines on dyslipidemia management.
- Analysis of the efficacy and cost-effectiveness of lipid-lowering therapies.
- Discussion of the 2019 European Society of Cardiology/European Atherosclerosis Society guidelines.
Main Results:
- Statins remain a cost-effective option for primary and secondary ASCVD prevention.
- PCSK9 inhibitors represent a significant advancement, offering potent LDL reduction.
- Personalized treatment strategies are essential for optimal patient outcomes.
Conclusions:
- Effective management of dyslipidemia is crucial for combating the rising ASCVD epidemic.
- A combination of established and novel therapies, guided by evidence-based recommendations, can optimize cardiovascular risk reduction.
- Adherence to updated clinical guidelines facilitates informed decision-making for improved patient care.
Abstract:
The incidence of atherosclerotic cardiovsacular disease (ASCVC) has increased in the developed countries. Dyslipidemia is a primary major risk factor for ASCVD and LDL lowering is one of the main objectives. Although treatment goals for dyslipidemias should be personalized in every patient, statins are cost-effective in primary and secondary prevention of ASCVD. New treatments with higher power and greater decreases in LDL, PSCK9 inhibitors, have made a new breakthrough in ASCVD treatment. The 2019 Guidelines for de Management of Dyslipidaemias: Lipid Modification to reduce Cardiovascular Risk (European Society of Cardiology/European Atherosclerosis Society) with the level of evidence and the strength of the recommendations can facilitate the best decisions and benefits to our patients in clinical practice.
More Related Videos
Related Concept Videos
Atherosclerosis III: Management
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Cholesterol: Significance and Regulation
Considering cholesterol and...
Coronary Artery Disease IV: Preventive Measures
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Lipids: Dietary Sources and Requirements

